Financial Performance - The company reported a revenue of 500 million yuan for the first half of 2024, representing a 20% increase compared to the same period last year[6]. - The company's operating revenue for the first half of 2024 was RMB 849,356,544.11, a decrease of 16.08% compared to RMB 1,012,077,288.18 in the same period last year[15]. - The net profit attributable to shareholders of the listed company was a loss of RMB 169,742,640.65, representing a decline of 287.30% from a profit of RMB 90,627,154.09 in the previous year[15]. - The net cash flow from operating activities was RMB 157,716,643.31, down 35.94% from RMB 246,209,748.37 in the same period last year[15]. - The total assets decreased by 3.65% to RMB 9,661,273,688.68 from RMB 10,027,159,630.47 at the end of the previous year[15]. - Basic earnings per share for the first half of 2024 were -0.23 yuan, a decrease of 291.67% compared to 0.12 yuan in the same period last year[16]. - The weighted average return on net assets was -2.08%, a decrease of 3.18 percentage points from 1.10% in the previous year[16]. - The company reported a net loss of RMB 23,535,770 from changes in the fair value of biological assets during the reporting period[16]. - The company reported a total non-recurring profit and loss of 28,652,307.04 RMB for the period, with significant contributions from government subsidies (8,901,549.99 RMB) and fair value changes of financial assets (9,798,498.01 RMB)[18]. Research and Development - Investment in R&D increased by 30% year-on-year, totaling 150 million yuan, focusing on innovative drug development and technology enhancements[6]. - The company has applied for 12 patents in drug quality research, with one granted and five published, enhancing its research capabilities[50]. - The company is expanding into human-derived multifunctional stem cell production and liver organoid platforms, aiming to provide iPSC reprogramming and organoid induction services[49]. - The company has developed a comprehensive drug screening platform that evaluates candidate molecules for efficacy, metabolism, and safety, enhancing development value[29]. - The company has established high-quality non-human primate experimental models, ensuring reliable data for drug safety evaluations[35]. Market Expansion and Strategy - The company expects a revenue growth forecast of 25% for the second half of 2024, driven by new product launches and market expansion strategies[6]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by the end of 2025[6]. - A strategic acquisition of a biotech firm is in progress, expected to enhance the company's capabilities in drug development and testing services[6]. - The company has launched two new products in Q2 2024, contributing to a 5% increase in overall sales volume[6]. Operational Efficiency - The gross profit margin improved to 45%, up from 40% in the previous year, reflecting better cost management and pricing strategies[6]. - The company has maintained a strong cash position with 300 million yuan in cash reserves, ensuring liquidity for future investments[6]. - The company emphasizes the importance of quality management and regulatory compliance in its service delivery to enhance operational efficiency[20]. - The company has established a systematic procurement management SOP to ensure compliance with GLP standards for the procurement of experimental models and related supplies[21]. Environmental Responsibility - The company emphasizes the importance of environmental protection, with water resource usage reported at 13,592 cubic meters for the company and 87,118 cubic meters for its subsidiary in the first half of the year[74]. - The company has implemented a comprehensive environmental management system, conducting regular inspections and third-party assessments of wastewater, noise, and air emissions[73]. - The company has committed to reducing carbon emissions through various measures, including the use of energy-efficient LED lighting and electric vehicles[80]. - The company has established a waste recycling agreement with third-party service providers to ensure proper waste management and disposal[77]. Talent and Human Resources - The company is experiencing a talent risk due to the long training cycle for industry professionals and the increasing difficulty in attracting and retaining talent[63]. - The company is implementing a talent development program to identify high-potential employees and enhance management capabilities[39]. - The company has a professional service team of 2,585 members as of June 30, 2024[40]. Compliance and Governance - The company received a warning letter from the China Securities Regulatory Commission regarding a 8.16% reduction in shareholding without timely disclosure[83]. - The company has strengthened its compliance with legal regulations following the warning letter received[83]. - There were no significant lawsuits or arbitration matters during the reporting period[83]. Financial Position - The total liabilities stood at CNY 1,746,032,260.24, slightly down from CNY 1,746,119,215.39, indicating a marginal decrease of 0.005%[98]. - The equity attributable to shareholders decreased to CNY 7,916,012,413.20 from CNY 8,279,315,724.35, a decline of approximately 4.39%[98]. - The company's current assets totaled CNY 5,492,884,034.54, down from CNY 7,121,967,340.11, indicating a decrease of about 22.87%[96]. - The company's inventory as of June 30, 2024, was CNY 1,632,144,111.85, down from CNY 1,863,081,944.56, a decrease of about 12.35%[96]. Shareholder Information - The total number of shares decreased from 749,888,699 to 749,477,334 after the repurchase and cancellation of 411,365 restricted shares[88]. - The top shareholder, Feng Yuxia, holds 167,160,633 shares, representing 22.29% of the total shares[89]. - HKSCC NOMINEES LIMITED is the second-largest shareholder with 118,975,060 shares, accounting for 15.87%[89]. - The company has repurchased 1,735,600 A shares, accounting for 0.2314% of total shares, with a total expenditure of approximately RMB 28.28 million[72].

重要内容提示： 每股分配比例 证券代码：603127 证券简称：昭衍新药 公告编号：2024-035 北京昭衍新药研究中心股份有限公司 2023 年年度 A 股 权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 A 股每股现金红利 0.16 元 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除息日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2024/7/30 | － | 2024/7/31 | 2024/7/31 | 差异化分红送转： 是 一、 通过分配方案的股东大会届次和日期 本次利润分配方案经公司 2024 年 6 月 20 日的 2023 年年度股东大会、2024 年第二次 A 股 类别股东会议及 2024 年第二次 H 股类别股东会议审议通过。 二、 分配方案 1. 发放年度：2023 年年度 2. 分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任公司上海分 公司（以下简称"中国结算上海分公司"）登记 ...

发言人 39:38 明白，然后刚才也提到有几个建设的投入，就不知道 pad pack 这块，咱们今年大概是就从数字化一点的， 大概是多少？应该就是 11 亿左右的规模，你做一个规就是全部加总在一起。对对对，就各个过去的措施， 未来就比如说明年或者再往后一点的时间，每年还是这个规划。我刚才也介绍了，就是新增的产能还是要 看需求，有需求我们才会释放，没有需求就是这些。 发言人 40:31 好的，我看现在线上也没有举手的投资者了。那咱们今天线上交流的这个成果也非常的充分。那就非常感 谢罗总的时间和各位投资者的参与。以后大家如果对公司有进一步的问题，也欢迎随时和朝阳的 IR 团队或 者和国生医药团队做进一步的交流。那么就谢谢罗总，谢谢各位投资者的参与，感谢大家，再见。好，谢 谢罗总，再见。 发言人 00:32 发言人 03:12 明白，然后刚才您也提到了价格这块的情况。现在看的话，这个价格战的大概是到了一个什么样的阶段？ 然后后续咱们觉得这个行业里面价格还有下降的可能性吗？从目前我们的价格在一季度到现在，一直到现 在，都是基本上是保持稳定的。其实应该说从去年年底到一季度到现在，基本上都是维持现在这样的一个 价格。我们 ...

Revenue and Profit Expectations - Expected revenue for the first half of 2024 is between RMB 719.50 million and RMB 973.44 million, a decrease of RMB 38.64 million to RMB 292.58 million compared to the same period last year, representing a decline of 3.8% to 28.9%[7][8] - Revenue for the first half of 2024 is RMB 1,012.08 million[4] - Expected net profit attributable to shareholders for the first half of 2024 is between RMB -184.36 million and RMB -136.26 million, indicating a loss compared to the same period last year[7] - Expected net profit attributable to shareholders after deducting non-recurring gains and losses for the first half of 2024 is between RMB -220.60 million and RMB -163.05 million[7] - Net profit attributable to shareholders after deducting non-recurring gains and losses for the first half of 2024 is RMB 76.89 million[4] - Earnings per share for the first half of 2024 is RMB 0.17[11] Business Segment Performance - Laboratory service business net profit for the first half of 2024 is expected to be between RMB -28.29 million and RMB 10.94 million[9] - Net profit from capital management is expected to contribute between RMB 49.60 million and RMB 54.82 million for the first half of 2024[9] Fair Value and Market Factors - Net loss from changes in the fair value of biological assets is expected to be between RMB 223.59 million and RMB 247.13 million for the first half of 2024[3] - The decline in revenue and net profit is attributed to reduced market demand, intensified competition, and a decrease in the fair value of biological assets[12][13]

证券代码：603127 证券简称：昭衍新药 公告编号：2024-033 北京昭衍新药研究中心股份有限公司 关于 2021 年 A 股限制性股票激励计划部分限制性股票 回购注销实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 回购注销原因： 鉴于目前国内外宏观经济、市场环境持续发生变化，若继续实施 2021 年 A 股 限制性股票激励计划将难以达到预期激励目的和效果。为更好地维护公司、股东 和员工的利益，有效调动核心员工的积极性，经慎重考虑，结合公司实际情况， 根据《上市公司股权激励管理办法》的有关规定，公司决定终止 2021 年 A 股限制 性股票激励计划并回购注销已授予尚未解除限售的限制性股票。综上，公司后续 将按照规定合计办理 41.1365 万股限制性股票的回购注销事宜。 本次注销股份的有关情况： 单位：股 | 回购股份数量 | 注销股份数量 | 注销日期 | | | | | --- | --- | --- | --- | --- | --- | | 411,365 | 411,365 | 202 ...

昭衍新药 2023 年年度股东大会、2024 年第二次 A 股类别股东会 议及 2024 年第二次 H 股类别股东会议会议资料 北京昭衍新药研究中心股份有限公司 2023 年年度股东大会、2024 年第二次 A 股类别股东 会议及 2024 年第二次 H 股类别股东会议 会议资料 2024 年 6 月 20 日 1 昭衍新药 2023 年年度股东大会、2024 年第二次 A 股类别股东会 议及 2024 年第二次 H 股类别股东会议会议资料 北京昭衍新药研究中心股份有限公司 2023 年年度股东大会、2024 年第二次 A 股类别股东会议及 2024 年第二次 H 股类别股东会议议程 一、投票方式：现场投票和网络投票相结合的方式 二、现场会议召开的时间和地点： 时间：2024 年 6 月 20 日 14 点 30 分 地点：北京市经济技术开发区荣华南路 12 号兴基铂尔曼酒店会议室 网络投票起止时间：自 2024 年 6 月 20 日至 2024 年 6 月 20 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时 间为股东大会召开当日的交易时间段，即 9:15-9:25, 9:30-11:30 ...

北京昭衍新药研究中心股份有限公司 关于召开 2023 年年度股东大会、2024 年第二次 A 股类别股 证券代码：603127 证券简称：昭衍新药 公告编号：2024-027 2023 年年度股东大会、2024 年第二次 A 股类别股东会议及 2024 年第二次 H 股类别股东会议 (二) 股东大会召集人：董事会 (三) 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票 相结合的方式 (四) 现场会议召开的日期、时间和地点 召开的日期时间：2024 年 6 月 20 日 14 点 30 分 召开地点：北京市经济技术开发区荣华南路 12 号兴基铂尔曼酒店会议室 股东大会召开日期：2024年6月20日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 (五) 网络投票的系统、起止日期和投票时间 东会议及 2024 年第二次 H 股类别股东会议的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (一) 股东大会类型和届次 网络投票系统：上海证券交易所股东大会 ...

证券代码：603127 证券简称：昭衍新药 公告编号：2024-028 北京昭衍新药研究中心股份有限公司 北京昭衍新药研究中心股份有限公司（以下简称"公司"或"昭衍新药"）于近 日收到上海证券交易所下发的《关于北京昭衍新药研究中心股份有限公司 2023 年年度报告的信息披露监管工作函》（上证公函【2024】0375 号）（以下简称 "《监管工作函》"），经公司及年审会计师核查，现对《监管工作函》内容回复 如下： 1.关于业务及业绩表现。公司 2023 年实现营业收入 23.76 亿元，同比增长 4.78%，归母净利润 3.97 亿元，同比下滑 63.04%，扣非净利润 3.38 亿元，同比 下滑 66.9%，主营业务毛利率 42.62%，同比减少 5.28 个百分点。细分业务中， 药物非临床研究服务实现营收 23.09 亿元，毛利率 43.22%，同比减少 5.09 个百 分点；临床服务及其他实现营收 6,342 万元，毛利率 21.18%，同比减少 10.52 个 百分点；实验模型供应实现营收 406 万元，毛利率 36.06%，同比增加 10.39 个百 分点。年报及相关公告披露公司业绩下滑的主要原因为， ...

M N 2 May 2024 CMB International Global Markets | Equity Research | Company Update Joinn Laboratories (6127 HK) Waiting longer for recovery to materialize Target Price HK$10.36 Joinn reported 1Q24 revenue of RMB325mn, down 12.1% YoY, and booked (Previous TP HK$14.41) attributable net loss of RMB272mn, a significant downturn from an attributable Up/Downside 24.6% net profit of RMB188mn in 1Q23. The 1Q24 revenue accounted for 13.4% of Current Price HK$8.31 our full-year estimate, in line with its historical a ...

Financial Performance - The company's operating revenue for Q1 2024 was RMB 324,809,103.67, representing a decrease of 12.07% compared to the same period last year[3]. - The net profit attributable to shareholders of the listed company was a loss of RMB 272,222,474.99, a decline of 244.98% year-on-year[3]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was a loss of RMB 280,666,741.34, down 251.92% year-on-year[3]. - The total revenue for Q1 2024 was CNY 324,809,103.67, a decrease of 12.0% compared to CNY 369,386,010.95 in Q1 2023[21]. - Net profit for Q1 2024 was a loss of CNY 273,363,603.07, compared to a profit of CNY 187,710,078.62 in Q1 2023[22]. - The total comprehensive income for Q1 2024 was a loss of CNY 272,499,809.53, compared to a profit of CNY 183,307,433.87 in Q1 2023[24]. - Basic earnings per share decreased by 244.00%[10]. - Diluted earnings per share also decreased by 244.00%[10]. - Basic earnings per share for Q1 2024 was CNY -0.36, compared to CNY 0.25 in Q1 2023[24]. Assets and Liabilities - The total assets at the end of the reporting period were RMB 9,733,254,487.30, a decrease of 2.93% from the end of the previous year[4]. - The equity attributable to shareholders of the listed company was RMB 7,993,144,600.58, down 3.46% from the end of the previous year[4]. - The company's total liabilities as of March 31, 2024, were RMB 1.74 billion, compared to RMB 1.75 billion at the end of the previous period, indicating a decrease of about 0.3%[19]. - The company's total equity attributable to shareholders decreased to CNY 7,993,144,600.58 from CNY 8,279,315,724.35 as of December 31, 2023[20]. - The company's total assets decreased from RMB 10.03 billion to RMB 9.73 billion, a decline of about 3%[18]. Cash Flow - The net cash flow from operating activities was RMB 119,953,519.31, not applicable for year-on-year comparison[3]. - The company reported a decrease in cash flow from operating activities due to reduced payments for experimental models[10]. - In Q1 2024, the cash inflow from operating activities was 492,589,961.10, a decrease of 22.4% compared to 635,825,537.05 in Q1 2023[27]. - The net cash flow from operating activities in Q1 2024 was 119,953,519.31, a significant improvement from a negative cash flow of –13,668,184.06 in Q1 2023[28]. - The cash inflow from investment activities in Q1 2024 was 111,453,520.72, down 50.0% from 222,354,944.59 in Q1 2023[29]. - The net cash flow from investment activities in Q1 2024 was –67,562,298.65, compared to a positive cash flow of 106,476,212.61 in Q1 2023[29]. - The cash outflow from financing activities in Q1 2024 was 37,928,364.49, an increase from 24,852,351.87 in Q1 2023[30]. - The net cash flow from financing activities in Q1 2024 was –37,928,364.49, worsening from –24,852,351.87 in Q1 2023[30]. - The cash and cash equivalents at the end of Q1 2024 amounted to 2,865,314,156.35, a decrease from 2,961,151,889.94 at the end of Q1 2023[30]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 74,233[11]. - The top ten shareholders held a total of 22.29% of shares, with the largest shareholder holding 167,160,633 shares[11]. Business Operations - The laboratory services business contributed a net profit of RMB -21,043,700, a decline of 130.01% year-on-year[5]. - The company signed new contracts worth RMB 400 million during the reporting period, with the number of new projects increasing by approximately 20% year-on-year, resulting in a total backlog of RMB 3.38 billion[15]. - The company emphasized the importance of monitoring investment risks due to various factors affecting order execution[15]. Non-Recurring Items - The company reported non-recurring gains and losses of RMB 8,444,300 for the reporting period[6]. - Non-recurring gains and losses amounted to a total of -82,637.33 and -558,720.76 respectively, with a tax impact of 1,422,161.37[8]. - The company has not identified any significant non-recurring gains or losses beyond those listed in the regulatory announcement[8]. Research and Development - The company reported a significant increase in research and development expenses, totaling CNY 22,967,298.39 in Q1 2024, down from CNY 27,611,585.58 in Q1 2023[21]. Fair Value Changes - The fair value change of biological assets resulted in a net loss of RMB 284,048,900[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses decreased by 251.92%, primarily due to reduced net profit from laboratory services and losses from changes in the fair value of biological assets[10]. Other Comprehensive Income - Other comprehensive income for Q1 2024 showed a net amount of CNY 863,793.54, compared to a loss of CNY -4,402,644.75 in Q1 2023[23]. - Investment income for Q1 2024 was CNY 6,972,038.25, a significant increase from CNY 514,120.05 in Q1 2023[22].